GTX-104: Novel Intravenous Nimodipine Formulation Shows Promise for Aneurysmal Subarachnoid Hemorrhage Treatment

Revolutionizing aSAH Therapy: Can GTX-104 Redefine Nimodipine Delivery?

A novel intravenous nimodipine formulation, GTX-104, has demonstrated comparable pharmacokinetics to oral nimodipine capsules with less variability and potentially improved safety profile in healthy volunteers, according to a recent Phase 1 randomized crossover study. The findings could have significant implications for the management of aneurysmal subarachnoid hemorrhage (aSAH), a devastating type of hemorrhagic stroke with high mortality rates that typically affects patients about two decades younger than those with ischemic stroke.

Nimodipine, a dihydropyridine calcium channel blocker, remains one of the few treatments proven effective for aSAH in controlled clinical trials. However, currently available oral formulations (tablets, capsules, and solutions) present numerous challenges in clinical practice. These include variable and low bioavailability, interference with feeding, high first-pass metabolism, and unpredictable plasma concentrations that can lead to dangerous hypotension. These issues are particularly problematic for aSAH patients who may be unconscious or intubated. While intravenous nimodipine is available in some countries, existing formulations contain high concentrations of ethanol (23.7% v/v) and polyethylene glycol 400 (17% v/v), which can cause liver toxicity, vascular irritation, and impair neurological assessment.

What Are the Key Design Elements of the GTX-104 Trial?

The study evaluated GTX-104, a sterile, aqueous-based nimodipine solution that avoids these problematic excipients. GTX-104 is a clear, colorless to light yellow solution containing nimodipine (2 mg/mL) with inactive ingredients including ultrapure polysorbate 80, dehydrated alcohol, and water for injection. The solution is diluted in common IV solutions to obtain a concentration of 0.08 mg/mL for infusion, composed of dispersed micelles of polysorbate 80 containing nimodipine and about 1.26% w/v alcohol. In this Phase 1 trial, 58 healthy adult volunteers participated in a two-period crossover design comparing GTX-104 administered as a 30-minute infusion of 4 mg every 4 hours plus a continuous infusion of 0.15 mg/h for 72 hours versus oral nimodipine capsules at 60 mg every 4 hours for the same duration. The primary endpoints were maximum plasma concentration after the first dose (Cmax Day 1 0-4h) and area under the concentration-time curve on Day 3 (AUC Day 3 0-24h), which represents steady-state exposure. The study also assessed safety parameters including treatment-emergent adverse events, vital signs, and clinical laboratory evaluations.

Results showed that GTX-104 achieved pharmacokinetic parameters comparable to oral nimodipine capsules. The geometric least squares mean Cmax Day 1 0-4h was 63 ng/mL for GTX-104 and 69 ng/mL for nimodipine capsules, with a ratio of 92% (90% CI: 82–104%). For AUC Day 3 0-24h, the values were 492 ng*h/mL for GTX-104 and 462 ng*h/mL for nimodipine capsules, with a ratio of 106% (90% CI: 99–114%). Notably, GTX-104 demonstrated significantly less variability in these parameters compared to oral nimodipine. The geometric coefficient of variation for Cmax Day 1 0-4h was 26% for GTX-104 versus 55% for nimodipine capsules, and for AUC Day 3 0-24h, it was 16% versus 38%, respectively. Both formulations showed similar median time to maximum concentration (Tmax) of approximately 0.5 hours.

Perhaps most significantly, the absolute bioavailability of GTX-104 was approximately 100%, compared to just 7.2% for oral nimodipine capsules. The geometric mean apparent total body clearance on Day 3 was 56 L/h for GTX-104 and 772 L/h for nimodipine capsules, reflecting this dramatic difference in bioavailability. Despite the higher bioavailability, GTX-104 did not show an increased risk of hypotension compared to oral nimodipine. In fact, hypotension (defined as systolic BP < 90 mmHg or diastolic BP < 60 mmHg) was less common with GTX-104 than with nimodipine capsules (33% versus 45% of subjects, respectively), likely due to the more consistent plasma concentrations achieved with the IV formulation.

Regarding safety, both formulations were generally well-tolerated. Treatment-emergent adverse events were reported in 76% of subjects receiving GTX-104 and 59% of those receiving nimodipine capsules. The most common adverse events included headache (36% in both groups), catheter site erythema (26% with GTX-104, none with capsules), somnolence (7% with GTX-104, 13% with capsules), and hot flushing (3% with GTX-104, 11% with capsules). Interestingly, fewer gastrointestinal disorders were reported with GTX-104 than with nimodipine capsules (7% versus 16%), while more administration site events were noted with GTX-104 (41% versus 11%). No serious adverse events occurred during the study, and there were no clinically significant changes in laboratory tests or electrocardiograms.

It's worth noting that prior to this study, GTX-104 had been administered to 104 healthy volunteers in a previous first-in-human study (GTX-104-001), which was a 4-part, single-center, randomized, dose-escalation and crossover study assessing safety, tolerability, pharmacokinetics, and absolute bioavailability. This earlier study found GTX-104 to be well-tolerated with only one treatment-emergent adverse event (infusion site extravasation) and no serious adverse events. Population pharmacokinetic modeling from this preliminary study served as the basis for the dosing regimen used in the current trial.

The current study utilized a sophisticated approach to sample size estimation, using an in silico population pharmacokinetic model developed from the previous Phase 1 data. This model accounted for food effects on absorption of oral doses and significant diurnal variation in bioavailability for the oral formulation. Under the hypothesis that the 90% confidence interval for the true geometric mean ratio would include 1 and fall within bioequivalence limits of 80-125%, 49 subjects were estimated to provide adequate statistical power. The study ultimately enrolled 60 subjects to ensure at least 50 completed the protocol.

Could Consistent Pharmacokinetics Lead to Better Outcomes?

The findings suggest that GTX-104 could potentially address many of the limitations associated with current nimodipine formulations for aSAH patients. The more consistent pharmacokinetic profile and reduced variability in plasma concentrations could lead to better blood pressure control, which is particularly important given that blood pressure variability has been associated with unfavorable outcomes after aSAH. The American Heart Association guidelines on aSAH emphasize that "close hemodynamic monitoring and blood pressure management to minimize blood pressure variability are beneficial." Furthermore, the improved bioavailability and more predictable response could potentially allow for more reliable dosing without compromising efficacy due to dose reductions necessitated by hypotension.

Previous research has highlighted the importance of maintaining nimodipine therapy in aSAH patients. Studies by Ditz and colleagues have shown that patients with reduction in nimodipine dosage due to hypotension had worse clinical and radiological outcomes, developed vasospasm and delayed cerebral ischemia significantly more often, and were more likely to have unfavorable outcomes. The potential for GTX-104 to maintain therapeutic levels with less risk of dose-limiting hypotension could therefore have important clinical implications.

While these results are promising, it's important to note that this study was conducted in healthy volunteers rather than aSAH patients. It remains to be seen whether the pharmacokinetic advantages and reduced incidence of hypotension observed with GTX-104 will translate to improved clinical outcomes in the target patient population. A Phase 3 randomized clinical trial of GTX-104 in aSAH patients was completed in January 2025, though results are not yet available. Additionally, GTX-104 may warrant investigation for other potential applications, such as intraarterial rescue therapy or intraventricular administration for angiographic vasospasm in aSAH patients, which are currently being explored with existing nimodipine formulations.

Could the more consistent pharmacokinetic profile of GTX-104 translate to better management of delayed cerebral ischemia, a common and devastating complication of aSAH? Might the ability to maintain therapeutic nimodipine levels without dose reductions due to hypotension lead to improved neurological outcomes? These questions highlight the potential significance of this novel formulation in addressing an important unmet need in neurocritical care. As we await the results of the Phase 3 trial, GTX-104 represents a promising advancement in the management of aSAH, potentially offering a more convenient, efficient, and controlled way to deliver nimodipine to these critically ill patients.

Are the Study Methods and Ethical Standards Robust?

This study adhered to consensus ethical principles from the Declaration of Helsinki and the Council for International Organizations of Medical Sciences International Ethical Guidelines, following applicable International Conference for Harmonization and Good Clinical Practice guidelines. The trial was conducted between August 2021 and February 2022, with all subjects providing written informed consent. The protocol design included a thorough analysis of blood pressure effects, with specific definitions for hypotension and heart rate abnormalities to carefully monitor cardiovascular responses to both formulations.

An important observation from the study relates to the variability in plasma concentrations between the two formulations. The maximum exposures (Cmax) on Day 3 for GTX-104 showed limited variability (geometric CV: 19-30%) over the six bolus doses, while nimodipine capsules exhibited much greater variability (geometric CV: 46-61%). This reduced variability with GTX-104 could be particularly beneficial in the clinical setting of aSAH where unpredictable fluctuations in drug levels may lead to hypotension and subsequent cerebral ischemia.

The study design included careful consideration of the pharmacokinetic profile of oral nimodipine capsules, which typically produces a sawtooth pattern with repeated dosing. The GTX-104 dosing regimen was specifically designed to replicate this pattern while maintaining similar magnitudes of peak and total exposure. This approach was developed in consultation with FDA scientists to ensure that the IV formulation would provide comparable therapeutic exposure to the approved oral formulation for aSAH treatment.

One noteworthy finding was the significant difference in bioavailability between formulations. Previous studies in aSAH patients have reported bioavailability of oral nimodipine ranging from 3-28%, with some patients showing undetectable plasma levels despite receiving the drug enterally. In this study, the absolute bioavailability of oral nimodipine capsules was determined to be approximately 7%, consistent with these earlier findings. The near 100% bioavailability of GTX-104 represents a substantial improvement, potentially allowing for more reliable drug delivery in critically ill patients.

The issue of hypotension with nimodipine therapy deserves special attention, as it represents a significant clinical challenge in aSAH management. Soppi and colleagues have previously reported inability to detect nimodipine in the plasma of 5 out of 8 aSAH patients despite administration of the drug enterally, highlighting the variability in absorption. When hypotension occurs with oral nimodipine, clinicians typically respond by reducing the dose or stopping the medication altogether, which may compromise efficacy. Studies have shown that such dose reductions are associated with increased risk of delayed cerebral ischemia and poor outcomes. The more predictable pharmacokinetic profile of GTX-104 could potentially reduce the need for dose adjustments, maintaining therapeutic efficacy while minimizing hypotensive episodes.

The study's crossover design provided important comparative data, with subjects serving as their own controls and minimizing the impact of inter-individual variability. The washout period of at least 96 hours between treatments was well beyond the typical requirement of five half-lives (nimodipine's plasma elimination half-life is 1.7-5.6 hours for oral capsules and 0.9-1.5 hours for IV formulation), ensuring complete clearance between treatment periods.

From a practical standpoint, the administration site reactions observed with GTX-104, while more frequent than with oral nimodipine, are likely of limited clinical significance in the target population of aSAH patients. These patients are typically managed in intensive care units with multiple vascular access sites already in place for monitoring and medication administration. The reduction in gastrointestinal side effects with GTX-104 compared to oral nimodipine capsules may be an additional benefit, particularly in critically ill patients who often experience gastrointestinal dysfunction.

The high protein binding of nimodipine likely explains why, despite 100% bioavailability with GTX-104, there was not an increased risk of hypotension. This characteristic leaves relatively little free drug available to act on vascular L-type calcium channels, providing a safety margin even with complete bioavailability. The more consistent plasma levels achieved with GTX-104 may actually reduce the risk of sudden hypotensive episodes that can occur with the variable peak concentrations seen with oral dosing.

What Future Prospects Does GTX-104 Hold for Neurocritical Care?

While this study represents an important step in the development of GTX-104, several questions remain to be addressed in future research. The translation of these pharmacokinetic advantages to clinical outcomes in aSAH patients is of paramount importance and will be addressed by the recently completed Phase 3 trial. Additionally, the potential applications of GTX-104 beyond standard aSAH management, including use as intraarterial or intraventricular rescue therapy for vasospasm, warrant further investigation. The favorable safety profile and improved pharmacokinetic characteristics of GTX-104 make it a promising candidate for these additional routes of administration, potentially expanding the therapeutic options for managing this devastating condition.

Summary

A Phase 1 randomized crossover study of 58 healthy volunteers has demonstrated that GTX-104, a novel intravenous nimodipine formulation, achieves pharmacokinetic parameters comparable to oral nimodipine capsules while exhibiting significantly less variability and a potentially improved safety profile. The study compared GTX-104 administered as a 30-minute infusion of 4 mg every 4 hours plus continuous infusion of 0.15 mg/h for 72 hours versus oral nimodipine capsules at 60 mg every 4 hours for the same duration. Results showed that GTX-104 achieved geometric least squares mean Cmax Day 1 of 63 ng/mL compared to 69 ng/mL for oral capsules, with a ratio of 92%, and AUC Day 3 of 492 ng*h/mL versus 462 ng*h/mL for oral capsules, with a ratio of 106%. Notably, GTX-104 demonstrated substantially reduced variability, with geometric coefficient of variation for Cmax of 26% versus 55% for oral capsules, and for AUC of 16% versus 38%. The absolute bioavailability of GTX-104 was approximately 100% compared to just 7.2% for oral nimodipine. Despite higher bioavailability, hypotension was less common with GTX-104 than with oral capsules (33% versus 45% of subjects). Both formulations were generally well-tolerated, with no serious adverse events. GTX-104 is a sterile, aqueous-based solution that avoids the high concentrations of ethanol and polyethylene glycol found in existing intravenous nimodipine formulations, which can cause liver toxicity and vascular irritation. These findings have significant implications for the management of aneurysmal subarachnoid hemorrhage, where current oral nimodipine formulations present challenges including variable bioavailability, interference with feeding, and unpredictable plasma concentrations that can lead to dangerous hypotension. The more consistent pharmacokinetic profile of GTX-104 could potentially allow for more reliable dosing and better blood pressure control, which is particularly important given that blood pressure variability has been associated with unfavorable outcomes after aSAH. A Phase 3 randomized clinical trial of GTX-104 in aSAH patients was completed in January 2025, though results are not yet available.